<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3321">
  <stage>Registered</stage>
  <submitdate>13/10/2011</submitdate>
  <approvaldate>13/10/2011</approvaldate>
  <nctid>NCT01453426</nctid>
  <trial_identification>
    <studytitle>Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers</studytitle>
    <scientifictitle>An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Adult Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym>109HV108</trialacronym>
    <secondaryid>109HV108</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BG00012 Dose 1
Treatment: drugs - BG00012 Dose 2

Experimental: Chinese Subjects - Dose 1 BG00012 - 

Experimental: Chinese Subjects - Dose 2 BG00012 - 

Experimental: Japanese Subjects - Dose 1 BG00012 - 

Experimental: Japanese Subjects - Dose 2 BG00012 - 

Experimental: Caucasian Subjects - Dose 1 BG00012 - 

Experimental: Caucasian Subjects - Dose 2 BG00012 - 


Treatment: drugs: BG00012 Dose 1


Treatment: drugs: BG00012 Dose 2


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>AUC of BG00012</outcome>
      <timepoint>First dose to 24 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Cmax of BG00012</outcome>
      <timepoint>First dose to 24 hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Adverse Events, as a measure of safety and tolerability</outcome>
      <timepoint>Subjects will be followed for the duration of the study, an expected 20 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Serious Adverse Events, as a measure of safety and tolerability</outcome>
      <timepoint>Subjects will be followed for the duration of the study, an expected 20 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Must give written informed consent and any authorizations required by local law

          -  All subjects must practice effective contraception during the study and be willing and
             able to continue contraception for 30 days after their last dose of study treatment.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History of any clinically significant cardiac, endocrine, hematologic, hepatic,
             immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric,
             and renal, or other major disease, as determined by the Investigator.

          -  History of malignancy (subjects with basal cell carcinoma that has been completely
             excised prior to study entry remain eligible)

          -  History of severe allergic or anaphylactic reactions

          -  Known history of or positive test result for Human Immunodeficiency Virus (HIV)

          -  Serious infection (e.g., pneumonia, septicemia) within 2 months prior to Screening.

          -  Female subjects who are pregnant or currently breastfeeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Basic Science</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>71</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Research Site - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biogen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an open-label, parallel-group study to evaluate the PK, safety, and tolerability of
      two different dose regimens of BG00012 over a 24-hour period to adult Chinese, Japanese, and
      Caucasian healthy volunteers.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01453426</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>